PMID- 29057274
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20221207
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2017
DP  - 2017
TI  - Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three 
      Korean Observational Studies (the VICTORY Study).
PG  - 5282343
LID - 10.1155/2017/5282343 [doi]
LID - 5282343
AB  - The present observational study aimed to evaluate the clinical effectiveness of 
      vildagliptin with metformin in Korean patients with type 2 diabetes mellitus 
      (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the 
      vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective 
      observational study of vildagliptin/metformin (fixed DC or free DC). The 
      effectiveness endpoint was the proportion of patients who achieved a glycemic 
      target (HbA1c) of </=7.0% at 24 weeks. In total, 4303 patients were included in the 
      analysis; of these, 2087 patients were eligible. The mean patient age was 
      56.99 +/- 11.25 years. Overall, 58.94% patients achieved an HbA1c target of </=7.0% 
      at 24 weeks. The glycemic target achievement rate was significantly greater in 
      patients with baseline HbA1c < 7.5% versus >/=7.5% (84.64% versus 43.97%), 
      receiving care at the hospital versus clinic (67.95% versus 52.33%), and 
      receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). 
      Multivariate logistic regression analysis indicated that disease duration (P < 
      0.0001), baseline HbA1c (P < 0.0001), and DC type (P = 0.0103) had significant 
      effects on drug effectiveness. Vildagliptin plus metformin appeared as an 
      effective treatment option for patients with T2DM in clinical practice settings 
      in Korea.
FAU - Suh, Sunghwan
AU  - Suh S
AD  - Division of Endocrinology, Dong-A University Medical Center, Dong-A University 
      School of Medicine, Busan, Republic of Korea.
FAU - Song, Sun Ok
AU  - Song SO
AD  - Division of Endocrinology, Department of Internal Medicine, National Health 
      Insurance Service, Ilsan Hospital, Ilsan, Republic of Korea.
FAU - Kim, Jae Hyeon
AU  - Kim JH
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical 
      Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Cho, Hyungjin
AU  - Cho H
AD  - Novartis Korea, Seoul, Republic of Korea.
FAU - Lee, Woo Je
AU  - Lee WJ
AUID- ORCID: 0000-0002-9605-9693
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Republic of Korea.
FAU - Lee, Byung-Wan
AU  - Lee BW
AUID- ORCID: 0000-0002-9899-4992
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170824
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/adverse effects/*analogs & derivatives/therapeutic use
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Chi-Square Distribution
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nitriles/adverse effects/*therapeutic use
MH  - Pyrrolidines/adverse effects/*therapeutic use
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vildagliptin
PMC - PMC5613692
EDAT- 2017/10/24 06:00
MHDA- 2018/06/19 06:00
PMCR- 2017/08/24
CRDT- 2017/10/24 06:00
PHST- 2017/04/14 00:00 [received]
PHST- 2017/06/03 00:00 [revised]
PHST- 2017/06/13 00:00 [accepted]
PHST- 2017/10/24 06:00 [entrez]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/08/24 00:00 [pmc-release]
AID - 10.1155/2017/5282343 [doi]
PST - ppublish
SO  - J Diabetes Res. 2017;2017:5282343. doi: 10.1155/2017/5282343. Epub 2017 Aug 24.